EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 4 (Avril 2020) Med Sci (Paris), 36 4 (2020) 341-347 References
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 4, Avril 2020
Page(s) 341 - 347
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020060
Published online 01 May 2020
  1. Lacroix-Desmazes S, Navarrete A-M, André S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008 ; 112 : 240–249. [Google Scholar]
  2. Ing M, Gupta N, Teyssandier M, et al. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol 2016 ; 301 : 40–48. [Google Scholar]
  3. Teyssandier M, André S, Gupta N, et al. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro. Haemophilia 2013 ; 19 : 399–402. [CrossRef] [PubMed] [Google Scholar]
  4. Pfistershammer K, Stöckl J, Siekmann J, et al. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006 ; 96 : 309–316. [CrossRef] [PubMed] [Google Scholar]
  5. Skupsky J, Zhang A-H, Su Y, et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009 ; 114 : 4741–4748. [Google Scholar]
  6. Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 2012 ; 120 : 2512–2520. [Google Scholar]
  7. Gangadharan B, Delignat S, Ollivier V, et al. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. J Thromb Haemost 2014 ; 12 : 2065–2069. [CrossRef] [PubMed] [Google Scholar]
  8. Lai JD, Moorehead PC, Sponagle K, et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in hemophilia A mice via chemotactic antigen competition. Blood 2016 ; 127 : 3439–3449. [Google Scholar]
  9. Platokouki H, Fischer K, Gouw SC, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia 2018 ; 24 : 283–290. [CrossRef] [PubMed] [Google Scholar]
  10. Dimitrov JD, Dasgupta S, Navarrete A-M, et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 2010 ; 115 : 2682–2685. [Google Scholar]
  11. Peyron I, Dimitrov JD, Delignat S, et al. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice. Haemoph Off J World Fed Hemoph 2015 ; 21 : e94–e98. [CrossRef] [Google Scholar]
  12. Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010 ; 16 : 256–262. [CrossRef] [PubMed] [Google Scholar]
  13. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012 ; 18 : e18–e20. [CrossRef] [PubMed] [Google Scholar]
  14. Sakaguchi S, Vignali DAA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013 ; 13 : 461–467. [PubMed] [Google Scholar]
  15. Hu G-L, Okita DK, Diethelm-Okita BM, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003 ; 1 : 2159–2166. [CrossRef] [PubMed] [Google Scholar]
  16. Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000 ; 84 : 643–652. [CrossRef] [PubMed] [Google Scholar]
  17. Meunier S, Menier C, Marcon E, et al. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv 2017 ; 1 : 1842–1847. [Google Scholar]
  18. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J 2011 ; 25 : 2040–2048. [CrossRef] [PubMed] [Google Scholar]
  19. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010 ; 116 : 4542–4545. [Google Scholar]
  20. Pinto S, Michel C, Schmidt-Glenewinkel H, et al. Overlapping gene coexpression patterns in human medullary thymic epithelial cells generate self-antigen diversity. Proc Natl Acad Sci U S A 2013 ; 110 : E3497–E3505. [CrossRef] [PubMed] [Google Scholar]
  21. Hu GL, Okita DK, Diethelm-Okita BM, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003 ; 1 : 2159–2166. [CrossRef] [PubMed] [Google Scholar]
  22. Kamaté C, Lenting PJ, Van Den Berg HM, et al. Depletion of CD4+ /CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J Thromb Haemost 2007 ; 5 : 611–613. [CrossRef] [PubMed] [Google Scholar]
  23. Algiman M, Dietrich G, Nydegger UE, et al. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992 ; 89 : 3795–3799. [CrossRef] [Google Scholar]
  24. Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013 ; 121 : 1039–1048. [Google Scholar]
  25. Hofbauer CJ, Whelan SFJ, Hirschler M, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015 ; 125 : 1180–1188. [Google Scholar]
  26. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994 ; 94 : 1496–1505. [CrossRef] [PubMed] [Google Scholar]
  27. Sakurai Y, Shima M, Tanaka I, et al. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors. Haematologica 2004 ; 89 : 696–703. [PubMed] [Google Scholar]
  28. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002 ; 8 : 23–29. [CrossRef] [PubMed] [Google Scholar]
  29. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016 ; 374 : 2054–2064. [Google Scholar]
  30. Gouw SC, van der Bom JG. Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007 ; 109 : 4648–4654. [Google Scholar]
  31. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011 ; 117 : 6367–6370. [Google Scholar]
  32. Jagger AT, Shimojima Y, Goronzy JJ, et al. T regulatory cells and the immune aging process. Gerontology 2014 ; 60 : 130–137. [CrossRef] [PubMed] [Google Scholar]
  33. Pautard B D’oiron R, Li Thiao Te V, et al. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. J. Thromb Haemost 2011 ; 9 : 1163–1170. [CrossRef] [PubMed] [Google Scholar]
  34. Gilles JG, Desqueper B, Lenk H, et al. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996 ; 97 : 1382–1388. [CrossRef] [PubMed] [Google Scholar]
  35. Repesse Y, Peyron I, Dimitrov JD, et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013 ; 98 : 1650–1655. [CrossRef] [PubMed] [Google Scholar]
  36. Matino D, Gargaro M, Santagostino E, et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest 2015 ; 125 : 3766–3781. [CrossRef] [PubMed] [Google Scholar]
  37. Moghimi B, Sack BK, Nayak S, et al. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 2011 ; 9 : 1524–1533. [CrossRef] [PubMed] [Google Scholar]
  38. Hassan S, Fijnvandraat K, van der Bom JG, et al. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A: what can we learn from other disorders?. Semin Thromb Hemost 2018 ; 44 : 531–543. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.